TS
NKTR icon

Thomas Steyer’s Nektar Therapeutics NKTR Stock Holding History

Thomas Steyer’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,000
Closed -$288K – 151
2026
Q1 		$288K Buy
+4,000
New +$228K ﹤0.01% 124
2025
Q4 		– Sell
-791,000
Closed -$45M – 164
2025
Q3 		$45M Buy
+791,000
New +$26.2M 0.18% 60
2014
Q2 		– Sell
-12,333
Closed -$2.24M – 107
2014
Q1 		$2.24M Sell
12,333
-28,334
-70% -$5.61M 0.04% 74
2013
Q4 		$6.92M Hold
40,667
– – 0.14% 62
2013
Q3 		$6.38M Buy
+40,667
New +$7.52M 0.13% 62

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Thomas Steyer's NKTR Position: Q2 2026 in Review

Thomas Steyer sold out of Nektar Therapeutics (NKTR) in Q2 2026, closing a stake of 4,000 shares — an estimated $288K sold.

Thomas Steyer first reported a position in NKTR in Q3 2013 and held it in 5 quarters. The position peaked at $45M in Q3 2025. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Thomas Steyer reported no remaining Nektar Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Thomas Steyer sold 4,000 Nektar Therapeutics shares in Q2 2026, an estimated $288K.
  • Thomas Steyer first reported a position in Nektar Therapeutics in Q3 2013 and held it in 5 quarters.
  • Thomas Steyer's Nektar Therapeutics position peaked at $45M in Q3 2025.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.